Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | TDP2 | O95551 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083495 | 0.96 | PNMT (0.61) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL467557 | 0.94 | PNMT (0.59) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL9483063 | 0.91 | PNMT (0.65) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL30709850 | 0.91 | PNMT (0.65) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL5145572 | 0.86 | PNMT (0.51) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL10229556 | 0.86 | TDP2 (0.49) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL467503 | 0.84 | PNMT (0.57) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL29119402 | 0.83 | LMNA (0.50) | PNMTADRA2ARAB9APOLBNPC1 | |
| SCHEMBL717840 | 0.82 | PNMT (0.81) | PNMTADRA2AMEN1RAB9AKMT2A | |
| SCHEMBL2061267 | 0.82 | PNMT (0.56) | PNMTADRA2AMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-217697975-U | Rectifying device for separating 4-nitroindan and 5-nitroindan | 天津和信德生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4703350-A1 | METHOD FOR PREPARING 4-AMINOINDAN AND METHOD FOR PREPARING DIHYDROINDENYL-PYRAZOLO[3,4-B]PYRIDINE-AMINE | JW Pharmaceutical Corporation (KR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4703351-A1 | METHOD OF PREPARING 4-AMINOINDAN AND METHOD OF PREPARING DIHYDROINDENYL-PYRAZOLO[3,4-B]PYRIDINE-AMINE COMPOUND | JW Pharmaceutical Corporation (KR) | 2026-03-04 | — | — | EP | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025096751-A1 | MACROCYCLIC INHIBITORS OF ATP CITRATE LYASE | ESPERION THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-119365467-A | Aza-tetraepoxy aza compounds and uses thereof | 基因泰克公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024224297-A1 | METHOD FOR PREPARING 4-AMINOINDAN AND METHOD FOR PREPARING DIHYDROINDENYL-PYRAZOLO[3,4-B]PYRIDINE-AMINE | 제이더블유중외제약 주식회사 | 2024-10-31 | — | — | WO | disclosed |
| WO-1998004521-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0337765-B1 | ACYLSULFONAMIDE DERIVATIVES OF ALPHA-CARBOCYCLYLTOLUIC ACIDS USED AS LEUKOTRIENE ANTAGONISTS | ICI AMERICAS INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| CN-1016506-B | Preparation method of 1, 2-indane sulfonamide compound with antiarrhythmic drug activity | PFIZER LTD (GB) | 1992-05-06 | — | — | CN | disclosed |
| US-5095038-A | Antiinflammatory, antiallergens | ICI AMERICAS INC. (US) | 1992-03-10 | — | — | US | disclosed |
| CN-1038449-A | Antiarrhythmics | PFIZER LTD (GB) | 1990-01-03 | — | — | CN | disclosed |
| EP-0337765-A2 | Acylsulfonamide derivatives of alpha-carbocyclyltoluic acids used as leukotriene antagonists | ICI AMERICAS INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| CN-87100658-A | 1,4-benzoxazine derivatives, their preparation and application | — | 1987-09-09 | — | — | CN | disclosed |
| US-4599347-A | ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | disclosed |
| US-4554280-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-11-19 | — | — | US | disclosed |
| US-4435406-A | 2-PYRIDYL DERIVATIVES OF 1,3-DIOXOLO(4,5-F)BENZIMIDAZOLE RING COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 1984-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | PNMT 526/4885ADRA2A 1386/4885MEN1 2884/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | PNMT 4412/4885ADRA2A 752/4885MEN1 1822/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | PNMT 526/4885ADRA2A 1386/4885MEN1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.